UB Paderborn / Katalog / Suche / in CDI

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

Cancer, 2001-11, Vol.92 (9), p.2247-2258

2001

Link zum Volltext

Verfügbarkeit prüfen

Triple Negative Breast Cancer: A Tale of Two Decades

Anti-cancer agents in medicinal chemistry, 2017-01, Vol.17 (4), p.491

2017

Link zum Volltext

Verfügbarkeit prüfen

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

NPJ breast cancer, 2021-09, Vol.7 (1), p.124-124, Article 124

2021

Link zum Volltext

Verfügbarkeit prüfen

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Oncotarget, 2018-04, Vol.9 (28), p.19463-19468

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of aromatase inhibitors in the treatment of breast cancer

Therapeutics and clinical risk management, 2008-02, Vol.4 (1), p.189-204

Nabholtz, Jean-Marc A

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictive and prognostic significance of CD8 + tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy

Oncology letters, 2017-07, Vol.14 (1), p.337-344

2017

Link zum Volltext

Verfügbarkeit prüfen

The emerging role of aromatase inhibitors in the adjuvant management of breast cancer

Reviews on recent clinical trials, 2006-09, Vol.1 (3), p.237

2006

Link zum Volltext

Verfügbarkeit prüfen

Ocular toxicity and cancer chemotherapy: A review

Cancer, 1996-10, Vol.78 (7), p.1359-1373

1996

Link zum Volltext

Verfügbarkeit prüfen

Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux : une approche pragmatique

Bulletin du cancer, 2011-07, Vol.98 (7), p.807-825

2011

Link zum Volltext

Verfügbarkeit prüfen

New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (herceptin)

Seminars in oncology, 2001-02, Vol.28 (1D), p.1-12, Article asonc0280001d

2001

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel in the treatment of breast cancer: current experience and future prospects

Expert review of anticancer therapy, 2005-08, Vol.5 (4), p.613-633

2005

Link zum Volltext

Verfügbarkeit prüfen

Main implications related to the switch to BRCA 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Oncotarget, 2018-04, Vol.9 (28), p.19463-19468

2018

Link zum Volltext

Verfügbarkeit prüfen

Taxane therapy for early stage breast cancer

Women's Health, 2006-01, Vol.2 (1), p.99-114

2006

Link zum Volltext

Verfügbarkeit prüfen

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.596-596

2022

Link zum Volltext

Verfügbarkeit prüfen

Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer

Indian journal of surgical oncology, 2010, Vol.1 (1), p.19-26

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1031-1031

2015

Link zum Volltext

Verfügbarkeit prüfen

Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.594-594

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-2-01: tnAcity: A phase II/III trial of nab -paclitaxel ( nab -P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT2-2-01-OT2-2-01

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1819: Heterogeneity of triple-negative breast cancer response to neoadjuvant treatment: tumor EGFR, HER3 and MET expressions can provide clues for therapy tailoring

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1819-1819

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 550: Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.550-550

2014

Link zum Volltext

Verfügbarkeit prüfen

An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS646-TPS646

2012

Link zum Volltext

Verfügbarkeit prüfen

tnAcity: A phase II/III trial of weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS1146-TPS1146

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-19-07

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4669: Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4669-4669

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma : Results of two randomized trials designed for combined analysis

Triple Negative Breast Cancer: A Tale of Two Decades

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Long-term safety of aromatase inhibitors in the treatment of breast cancer

Predictive and prognostic significance of CD8 + tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy

The emerging role of aromatase inhibitors in the adjuvant management of breast cancer

Ocular toxicity and cancer chemotherapy: A review

Le cancer du sein sans envahissement ganglionnaire. Au-delà des consensus internationaux : une approche pragmatique

New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (herceptin)

Docetaxel in the treatment of breast cancer: current experience and future prospects

Main implications related to the switch to BRCA 1/2 tumor testing in ovarian cancer patients: a proposal of a consensus

Taxane therapy for early stage breast cancer

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant

Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid

Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial

Abstract OT2-2-01: tnAcity: A phase II/III trial of nab -paclitaxel ( nab -P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)

Abstract 1819: Heterogeneity of triple-negative breast cancer response to neoadjuvant treatment: tumor EGFR, HER3 and MET expressions can provide clues for therapy tailoring

Abstract 550: Genomic instability and telomere characteristics as predictive biomarkers of therapeutic response in triple-negative breast cancer

tnAcity: A phase II/III trial of weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC)

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

Abstract 4669: Response to the anti-EGFR antibody panitumumab combined with standard neoadjuvant chemotherapy in triple negative breast cancer (TNBC): the immune and IGFR pathways

Aktive Filter

Suchergebnisse filtern